William Blair Reaffirms Their Buy Rating on Ikena Oncology (IKNA)
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 29 2024
0mins
Should l Buy ?
Source: Business Insider
Analyst Rating: William Blair analyst Matt Phipps has maintained a Buy rating on Ikena Oncology (IKNA), which closed at $1.54, with a Moderate Buy consensus and an average price target of $4.00.
Company Overview: Ikena Oncology focuses on developing innovative cancer therapies targeting specific signaling pathways, currently advancing five clinical and discovery programs.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
